ArticleOphthalmology and therapy2019
Near Vision Improvement with the Use of a New Topical Compound for Presbyopia Correction: A Prospective, Consecutive Interventional Non-Comparative Clinical Study.
Article in Ophthalmology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% Bromfenac.Indian journal of ophthalmology · 2026Trial
- Presbyopia: Current Perspectives and Prospects for Patients.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- A Comparative Clinical Study of 0.50% Versus 0.75% Pilocarpine Eye Drops for Improving Visual Performance in Presbyopia.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- The Science of Pseudoaccommodation and Its Therapeutic Potential.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Evaluating Pilocarpine 1% Eye Drops in Presbyopia: A Triple-Blinded Randomized Trial.Journal of ophthalmology · 2026Article
- Pharmacological Modulation of Pupil Size in Presbyopia: Optical Modeling and Clinical Implications.Journal of clinical medicine · 2025Article
- Pilocarpine 1% for Improved Near Vision in Pseudophakic Patients.Journal of ophthalmic & vision research · 2025Article
- Pilocarpine in the Treatment of Presbyopia: Progress, Issues, and Future Prospects.Drugs & aging · 2024Review
- Non-Miotic Improvement in Binocular Near Vision with a Topical Compound Formula for Presbyopia Correction.Ophthalmology and therapy · 2023Article
- Pharmacological Treatments for Presbyopia.Drugs & aging · 2023Article
- New insights in presbyopia: impact of correction strategies.BMJ open ophthalmology · 2023Review
- Correction of presbyopia.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Pharmacological treatment of presbyopia: A systematic review.European journal of translational myology · 2022Article
- Pharmacological Treatment in Presbyopia.Journal of clinical medicine · 2022Review
- A multicentric study of pharmacological treatment for presbyopia.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Presbyopia Treatments by Mechanism of Action: A New Classification System Based on a Review of the Literature.Clinical ophthalmology (Auckland, N.Z.) · 2021Review
- Pharmacological Therapy for Presbyopia in Patients with Previous Corneal Refractive Surgery: A Pilot Study.Ophthalmology and therapy · 2020Article
- Presbyopia Treatment With Eye Drops: An Eight Year Retrospective Study.Translational vision science & technology · 2020Article
- A Systematic Review and Meta-Analysis on the Efficacy and Safety of Topical Pilocarpine 1.25% in Presbyopia Treatment.Journal of current ophthalmologyReview
- A Review of Pharmacological Presbyopia Treatment.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo report the outcomes in near vision, optical quality and pupil diameter of a new pharmacological therapy (FOV tears) for presbyopia.
methodsThis was a prospective, consecutive, interventional, non-comparative clinical study in which 117 presbyopic patients were given one drop of the novel therapy (FOV tears) in each eye, followed 2 h after the instillation of the eye drop by an evaluation of the binocular uncorrected near visual acuity (UNVA) and uncorrected distance visual acuity. The objective scatter index and pupil diameter under photopic and scotopic conditions before and after instillation were also assessed. The patients were divided into two groups according to their age, with group 1 patients being 41 and 50 years old and group 2 patients, between 51 and 65 years old.
resultsThe mean age of the patients was 50.2 years. The mean UNVA before the use of the eye drop was 0.35 LogMAR, which improved to 0.16 LogMAR at 2 h after the use of the eye drop (p = 0.000). Nine patients did not show an improvement in UNVA, but no patient showed a loss of lines. Fourteen patients (11.9%) reported headaches as a side effect of the therapy.
conclusionThis pharmacological therapy improved near vision by one or more lines (mean improvement 0.18 lines) in 92.3% of the patients at 2 h following the instillation of the eye drops. The group with the youngest patients gained more lines than the group with the oldest patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.